ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update November 13, 2020
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients October 26, 2020
ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update August 14, 2020
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development July 20, 2020
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation June 17, 2020
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc. May 26, 2020
